Work

A first-in-human, phase I pharmacodynamic (PD) and pharmacokinetic (PK) study of BNC105P, a novel vascular disrupting agent (VDA) and inhibitor of cancer cell proliferation.

Year: 2010

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2010.28.15_suppl.3054

Authors: G. Chong, J. Desai, D. C. Bibby, G. Kremmidiotis, S. S. Wong, A. F. Leske, C. A. Matthews, M. A. Rosen, D. Rischin

Language: English

Topic: Angiogenesis and VEGF in Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2475534444

Cites:

Cited by: 3

Related to: 10